메뉴 건너뛰기




Volumn 22, Issue 5, 2013, Pages 569-578

Hsp90 inhibitors in breast cancer: A systematic review

Author keywords

Alvespimycin; Breast cancer; Hsp90 inhibitors; Retaspimycin; Tanespimycin

Indexed keywords

ALVESPIMYCIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIIB 021; CISPLATIN; CNF 2024; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GANETESPIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IRINOTECAN; LAPATINIB; LUMINESPIB; NUCLEOSIDE ANALOG; PACLITAXEL; PF 04929113; PRODRUG; RETASPIMYCIN; SNX 2112; SNX 5422; TAMOXIFEN; TANESPIMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

EID: 84884132829     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.06.003     Document Type: Review
Times cited : (60)

References (55)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American Cancer Society, American Cancer Society, Atlanta, [accessed at 10.04.13]
    • American Cancer Society Cancer facts & figures 2012 2012, American Cancer Society, Atlanta, [accessed at 10.04.13]. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics.
    • (2012) Cancer facts & figures 2012
  • 2
    • 80052714639 scopus 로고    scopus 로고
    • Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • ESMO Guidelines Working Group
    • Cardoso F., Fallowfield L., Costa A., Castiglione M., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl.6):vi25-vi30. ESMO Guidelines Working Group.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL.6
    • Cardoso, F.1    Fallowfield, L.2    Costa, A.3    Castiglione, M.4    Senkus, E.5
  • 4
    • 0021708673 scopus 로고
    • Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies
    • Lai B.T., Chin N.W., Stanek A.E., Keh W., Lanks K.W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984, 4:2802-2810.
    • (1984) Mol Cell Biol , vol.4 , pp. 2802-2810
    • Lai, B.T.1    Chin, N.W.2    Stanek, A.E.3    Keh, W.4    Lanks, K.W.5
  • 5
    • 84857039457 scopus 로고    scopus 로고
    • Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
    • Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012, 1823:742-755.
    • (2012) Biochim Biophys Acta , vol.1823 , pp. 742-755
    • Jhaveri, K.1    Taldone, T.2    Modi, S.3    Chiosis, G.4
  • 6
    • 33846861747 scopus 로고    scopus 로고
    • Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
    • Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13:S125-S135.
    • (2006) Endocr Relat Cancer , vol.13
    • Powers, M.V.1    Workman, P.2
  • 7
    • 84874267225 scopus 로고    scopus 로고
    • The therapeutic target Hsp90 and cancer hallmarks
    • Miyata Y., Nakamoto H., Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 2013, 19:347-365.
    • (2013) Curr Pharm Des , vol.19 , pp. 347-365
    • Miyata, Y.1    Nakamoto, H.2    Neckers, L.3
  • 8
    • 84863872604 scopus 로고    scopus 로고
    • Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    • De Mattos-Arruda L., Cortes J. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?. Breast 2012, 21:604-607.
    • (2012) Breast , vol.21 , pp. 604-607
    • De Mattos-Arruda, L.1    Cortes, J.2
  • 9
    • 0141596939 scopus 로고    scopus 로고
    • Structure and functional relationships of Hsp90
    • Prodromou C., Pearl L.H. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003, 3:301-323.
    • (2003) Curr Cancer Drug Targets , vol.3 , pp. 301-323
    • Prodromou, C.1    Pearl, L.H.2
  • 10
    • 84872011968 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
    • Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. JClin Epidemiol 2009, 62:e1-34.
    • (2009) JClin Epidemiol , vol.62
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3    Mulrow, C.4    Gøtzsche, P.C.5    Ioannidis, J.P.6
  • 11
    • 84866375177 scopus 로고    scopus 로고
    • Aphase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
    • Jhaveri K., Miller K., Rosen L., Schneider B., Chap L., Hannah A., et al. Aphase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 2012, 18:5090-5098.
    • (2012) Clin Cancer Res , vol.18 , pp. 5090-5098
    • Jhaveri, K.1    Miller, K.2    Rosen, L.3    Schneider, B.4    Chap, L.5    Hannah, A.6
  • 12
    • 84856217356 scopus 로고    scopus 로고
    • Aphase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
    • Gartner E.M., Silverman P., Simon M., Flaherty L., Abrams J., Ivy P., et al. Aphase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat 2012, 131:933-937.
    • (2012) Breast Cancer Res Treat , vol.131 , pp. 933-937
    • Gartner, E.M.1    Silverman, P.2    Simon, M.3    Flaherty, L.4    Abrams, J.5    Ivy, P.6
  • 13
    • 79960985354 scopus 로고    scopus 로고
    • HSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    • Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17:5132-5139.
    • (2011) Clin Cancer Res , vol.17 , pp. 5132-5139
    • Modi, S.1    Stopeck, A.2    Linden, H.3    Solit, D.4    Chandarlapaty, S.5    Rosen, N.6
  • 14
    • 36849055007 scopus 로고    scopus 로고
    • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breastcancer: a phase I dose-escalation study
    • Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breastcancer: a phase I dose-escalation study. JClin Oncol 2007, 25:5410-5417.
    • (2007) JClin Oncol , vol.25 , pp. 5410-5417
    • Modi, S.1    Stopeck, A.T.2    Gordon, M.S.3    Mendelson, D.4    Solit, D.B.5    Bagatell, R.6
  • 15
    • 84859794081 scopus 로고    scopus 로고
    • Aphase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
    • Iyer G., Morris M.J., Rathkopf D., Slovin S.F., Steers M., Larson S.M., et al. Aphase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 2012, 69:1089-1097.
    • (2012) Cancer Chemother Pharmacol , vol.69 , pp. 1089-1097
    • Iyer, G.1    Morris, M.J.2    Rathkopf, D.3    Slovin, S.F.4    Steers, M.5    Larson, S.M.6
  • 16
    • 34250197902 scopus 로고    scopus 로고
    • Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    • Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
    • (2007) Clin Cancer Res , vol.13 , pp. 1775-1782
    • Solit, D.B.1    Ivy, S.P.2    Kopil, C.3    Sikorski, R.4    Morris, M.J.5    Slovin, S.F.6
  • 17
    • 23044441106 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
    • Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. JClin Oncol 2005, 23:4152-4161.
    • (2005) JClin Oncol , vol.23 , pp. 4152-4161
    • Banerji, U.1    O'Donnell, A.2    Scurr, M.3    Pacey, S.4    Stapleton, S.5    Asad, Y.6
  • 18
    • 20944444881 scopus 로고    scopus 로고
    • Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    • Ramanathan R.K., Trump D.L., Eiseman J.L., Belani C.P., Agarwala S.S., Zuhowski E.G., et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005, 11:3385-3391.
    • (2005) Clin Cancer Res , vol.11 , pp. 3385-3391
    • Ramanathan, R.K.1    Trump, D.L.2    Eiseman, J.L.3    Belani, C.P.4    Agarwala, S.S.5    Zuhowski, E.G.6
  • 19
    • 79952734485 scopus 로고    scopus 로고
    • Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
    • Pacey S., Wilson R.H., Walton M., Eatock M.M., Hardcastle A., Zetterlund A., et al. Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17:1561-1570.
    • (2011) Clin Cancer Res , vol.17 , pp. 1561-1570
    • Pacey, S.1    Wilson, R.H.2    Walton, M.3    Eatock, M.M.4    Hardcastle, A.5    Zetterlund, A.6
  • 20
    • 77951907072 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    • Ramanathan R.K., Egorin M.J., Erlichman C., Remick S.C., Ramalingam S.S., Naret C., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. JClin Oncol 2010, 28:1520-1526.
    • (2010) JClin Oncol , vol.28 , pp. 1520-1526
    • Ramanathan, R.K.1    Egorin, M.J.2    Erlichman, C.3    Remick, S.C.4    Ramalingam, S.S.5    Naret, C.6
  • 21
    • 58149180924 scopus 로고    scopus 로고
    • Aphase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    • Tse A.N., Klimstra D.S., Gonen M., Shah M., Sheikh T., Sikorski R., et al. Aphase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008, 14:6704-6711.
    • (2008) Clin Cancer Res , vol.14 , pp. 6704-6711
    • Tse, A.N.1    Klimstra, D.S.2    Gonen, M.3    Shah, M.4    Sheikh, T.5    Sikorski, R.6
  • 22
    • 50349093362 scopus 로고    scopus 로고
    • Aphase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    • Ramalingam S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., et al. Aphase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3456-3461.
    • (2008) Clin Cancer Res , vol.14 , pp. 3456-3461
    • Ramalingam, S.S.1    Egorin, M.J.2    Ramanathan, R.K.3    Remick, S.C.4    Sikorski, R.P.5    Lagattuta, T.F.6
  • 23
    • 79955603500 scopus 로고    scopus 로고
    • Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
    • Hubbard J., Erlichman C., Toft D.O., Qin R., Stensgard B.A., Felten S., et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011, 29:473-480.
    • (2011) Invest New Drugs , vol.29 , pp. 473-480
    • Hubbard, J.1    Erlichman, C.2    Toft, D.O.3    Qin, R.4    Stensgard, B.A.5    Felten, S.6
  • 24
    • 84856032294 scopus 로고    scopus 로고
    • Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer
    • Abstract 590
    • Modi S., Saura C., Henderson C.A., Lin N.U., Mahtani R.L., Goddard J., et al. Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. JClin Oncol 2011, 29. Abstract 590.
    • (2011) JClin Oncol , vol.29
    • Modi, S.1    Saura, C.2    Henderson, C.A.3    Lin, N.U.4    Mahtani, R.L.5    Goddard, J.6
  • 25
    • 51449115938 scopus 로고    scopus 로고
    • Aphase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
    • Abstract 14613
    • Bryson J.C., Infante J.R., Ramanathan R.K., Jones S.F., Von Hoff D.D., Burris H.A. Aphase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. JClin Oncol 2008, 26(Suppl.):636. Abstract 14613.
    • (2008) JClin Oncol , vol.26 , Issue.SUPPL. , pp. 636
    • Bryson, J.C.1    Infante, J.R.2    Ramanathan, R.K.3    Jones, S.F.4    Von Hoff, D.D.5    Burris, H.A.6
  • 26
    • 84857036694 scopus 로고    scopus 로고
    • Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer
    • Schroder C., Pederson J.V., Chua S., Swanton C., Akimov M., Ide S., et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. JClin Oncol 2011, 29:e11024.
    • (2011) JClin Oncol , vol.29
    • Schroder, C.1    Pederson, J.V.2    Chua, S.3    Swanton, C.4    Akimov, M.5    Ide, S.6
  • 27
    • 49849088582 scopus 로고    scopus 로고
    • Aphase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients
    • Abstract 3058
    • Haluska P., Toft D.O., Steinmetz S.M., Furth A., Mandrekar S., Stensgard B.A., et al. Aphase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients. JClin Oncol 2004, 22. Abstract 3058.
    • (2004) JClin Oncol , vol.22
    • Haluska, P.1    Toft, D.O.2    Steinmetz, S.M.3    Furth, A.4    Mandrekar, S.5    Stensgard, B.A.6
  • 28
    • 84874428053 scopus 로고    scopus 로고
    • Aphase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    • San Antonio, TX ; Abstract [P1-17-08]
    • Jhaveri K., Chandarlapaty S., Lake D., et al. Aphase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC). Proceedings of the 34th annual San Antonio breast cancer symposium 2011, San Antonio, TX ; Abstract [P1-17-08].
    • (2011) Proceedings of the 34th annual San Antonio breast cancer symposium
    • Jhaveri, K.1    Chandarlapaty, S.2    Lake, D.3
  • 29
    • 84857060835 scopus 로고    scopus 로고
    • Phase 1 dose escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2 metastatic breast cancer
    • San Antonio, TX D 8-#2013;12
    • Modi S., Ismail-Khan R., Munster P., et al. Phase 1 dose escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2 metastatic breast cancer. Proceedings of the 33rd annual San Antonio breast cancer symposium 2010 Dec 8-12, San Antonio, TX.
    • (2010) Proceedings of the 33rd annual San Antonio breast cancer symposium
    • Modi, S.1    Ismail-Khan, R.2    Munster, P.3
  • 30
    • 0031875042 scopus 로고    scopus 로고
    • The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
    • Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998, 42:273-279.
    • (1998) Cancer Chemother Pharmacol , vol.42 , pp. 273-279
    • Schulte, T.W.1    Neckers, L.M.2
  • 31
  • 32
    • 54349098717 scopus 로고    scopus 로고
    • Acombination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
    • Raja S.M., Clubb R.J., Bhattacharyya M., Dimri M., Cheng H., Pan W., et al. Acombination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008, 7:1630-1640.
    • (2008) Cancer Biol Ther , vol.7 , pp. 1630-1640
    • Raja, S.M.1    Clubb, R.J.2    Bhattacharyya, M.3    Dimri, M.4    Cheng, H.5    Pan, W.6
  • 35
    • 0034890377 scopus 로고    scopus 로고
    • Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters
    • Münster P.N., Basso A., Solit D., Norton L., Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001, 7:2228-2236.
    • (2001) Clin Cancer Res , vol.7 , pp. 2228-2236
    • Münster, P.N.1    Basso, A.2    Solit, D.3    Norton, L.4    Rosen, N.5
  • 36
    • 0038404927 scopus 로고    scopus 로고
    • Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
    • Solit D.B., Basso A.D., Olshen A.B., Scher H.I., Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003, 63:2139-2144.
    • (2003) Cancer Res , vol.63 , pp. 2139-2144
    • Solit, D.B.1    Basso, A.D.2    Olshen, A.B.3    Scher, H.I.4    Rosen, N.5
  • 37
    • 0033890818 scopus 로고    scopus 로고
    • Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents
    • Bagatell R., Paine-Murrieta G.D., Taylor C.W., Pulcini E.J., Akinaga S., Benjamin I.J., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000, 6:3312-3318.
    • (2000) Clin Cancer Res , vol.6 , pp. 3312-3318
    • Bagatell, R.1    Paine-Murrieta, G.D.2    Taylor, C.W.3    Pulcini, E.J.4    Akinaga, S.5    Benjamin, I.J.6
  • 39
    • 70350786146 scopus 로고    scopus 로고
    • Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration
    • Abstract #1435
    • Tao C., Yu C., De T.K., Everett N., Frankel T., Ci S., et al. Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration. Proc Amer Assoc Cancer Res 2005, 46. Abstract #1435.
    • (2005) Proc Amer Assoc Cancer Res , vol.46
    • Tao, C.1    Yu, C.2    De, T.K.3    Everett, N.4    Frankel, T.5    Ci, S.6
  • 40
    • 21244462689 scopus 로고    scopus 로고
    • Invivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
    • Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., et al. Invivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005, 56:115-125.
    • (2005) Cancer Chemother Pharmacol , vol.56 , pp. 115-125
    • Hollingshead, M.1    Alley, M.2    Burger, A.M.3    Borgel, S.4    Pacula-Cox, C.5    Fiebig, H.H.6
  • 41
    • 21244466289 scopus 로고    scopus 로고
    • Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) invitro: effects on Hsp90 and client proteins in melanoma models
    • Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) invitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005, 56:126-137.
    • (2005) Cancer Chemother Pharmacol , vol.56 , pp. 126-137
    • Smith, V.1    Sausville, E.A.2    Camalier, R.F.3    Fiebig, H.H.4    Burger, A.M.5
  • 42
    • 33751258297 scopus 로고    scopus 로고
    • Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
    • Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006, 103:17408-17413.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 17408-17413
    • Sydor, J.R.1    Normant, E.2    Pien, C.S.3    Porter, J.R.4    Ge, J.5    Grenier, L.6
  • 43
    • 79956001501 scopus 로고    scopus 로고
    • Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
    • Scaltriti M., Serra V., Normant E., Guzman M., Rodriguez O., Lim A.R., et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther 2011, 10:817-824.
    • (2011) Mol Cancer Ther , vol.10 , pp. 817-824
    • Scaltriti, M.1    Serra, V.2    Normant, E.3    Guzman, M.4    Rodriguez, O.5    Lim, A.R.6
  • 44
    • 68849084042 scopus 로고    scopus 로고
    • Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
    • Leow C.C., Chesebrough J., Coffman K.T., Fazenbaker C.A., Gooya J., Weng D., et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009, 8:2131-2141.
    • (2009) Mol Cancer Ther , vol.8 , pp. 2131-2141
    • Leow, C.C.1    Chesebrough, J.2    Coffman, K.T.3    Fazenbaker, C.A.4    Gooya, J.5    Weng, D.6
  • 45
    • 73149118593 scopus 로고    scopus 로고
    • Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status
    • Abstract B79
    • Sequist L., Janne P., Sweeney J., Walker J., Grayzel D., Lynch T. Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics 2007, Abstract B79.
    • (2007) AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics
    • Sequist, L.1    Janne, P.2    Sweeney, J.3    Walker, J.4    Grayzel, D.5    Lynch, T.6
  • 46
    • 51449118446 scopus 로고    scopus 로고
    • Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial
    • Abstract 10503
    • Wagner A.J., Morgan J.A., Chugh R., Rosen L.S., George S., Gordon M.S., et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. JClin Oncol 2008, 26(15 Suppl.). Abstract 10503.
    • (2008) JClin Oncol , vol.26 , Issue.15 SUPPL.
    • Wagner, A.J.1    Morgan, J.A.2    Chugh, R.3    Rosen, L.S.4    George, S.5    Gordon, M.S.6
  • 47
    • 84857042166 scopus 로고    scopus 로고
    • Aphase I doseescalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report
    • Abstract 3051
    • Cho D., Heath E.I., Cleary J.M., Kwak E.L., Gandhi L., Lawrence D.P., et al. Aphase I doseescalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report. JClin Oncol 2011, 29. Abstract 3051.
    • (2011) JClin Oncol , vol.29
    • Cho, D.1    Heath, E.I.2    Cleary, J.M.3    Kwak, E.L.4    Gandhi, L.5    Lawrence, D.P.6
  • 48
    • 79961009295 scopus 로고    scopus 로고
    • Aphase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors
    • Abstract 2529
    • Goldman J.W., Raju R.N., Gordon G.A., Vukovic V.M., Bradley R., Rosen L.S. Aphase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. JClin Oncol 2010, 28(Suppl.). Abstract 2529.
    • (2010) JClin Oncol , vol.28 , Issue.SUPPL.
    • Goldman, J.W.1    Raju, R.N.2    Gordon, G.A.3    Vukovic, V.M.4    Bradley, R.5    Rosen, L.S.6
  • 49
    • 80455162319 scopus 로고    scopus 로고
    • Aphase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas
    • Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., et al. Aphase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011, 17:6831-6839.
    • (2011) Clin Cancer Res , vol.17 , pp. 6831-6839
    • Rajan, A.1    Kelly, R.J.2    Trepel, J.B.3    Kim, Y.S.4    Alarcon, S.V.5    Kummar, S.6
  • 50
    • 55249118494 scopus 로고    scopus 로고
    • BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience
    • Abstract 2503
    • Elfiky A., Saif M.W., Beeram M., Brien O'., Lammanna N., Castron J.E., et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. JClin Oncol 2008, 26. Abstract 2503.
    • (2008) JClin Oncol , vol.26
    • Elfiky, A.1    Saif, M.W.2    Beeram, M.3    Brien, O.'.4    Lammanna, N.5    Castron, J.E.6
  • 51
    • 42349084306 scopus 로고    scopus 로고
    • NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
    • Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
    • (2008) Cancer Res , vol.68 , pp. 2850-2860
    • Eccles, S.A.1    Massey, A.2    Raynaud, F.I.3    Sharp, S.Y.4    Box, G.5    Valenti, M.6
  • 52
    • 48949119477 scopus 로고    scopus 로고
    • NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
    • Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10:R33.
    • (2008) Breast Cancer Res , vol.10
    • Jensen, M.R.1    Schoepfer, J.2    Radimerski, T.3    Massey, A.4    Guy, C.T.5    Brueggen, J.6
  • 53
    • 79960983822 scopus 로고    scopus 로고
    • AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies
    • Abstract 2528
    • Samuel T., Sessa C., Britten C., Milligan K.S., Mita M.M., Banerji U., et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. JClin Oncol 2010, 28. Abstract 2528.
    • (2010) JClin Oncol , vol.28
    • Samuel, T.1    Sessa, C.2    Britten, C.3    Milligan, K.S.4    Mita, M.M.5    Banerji, U.6
  • 55
    • 84865794941 scopus 로고    scopus 로고
    • Molecular pathways: targeting hsp90-who benefits and who does not
    • Scaltriti M., Dawood S., Cortes J. Molecular pathways: targeting hsp90-who benefits and who does not. Clin Cancer Res 2012, 18:4508-4513.
    • (2012) Clin Cancer Res , vol.18 , pp. 4508-4513
    • Scaltriti, M.1    Dawood, S.2    Cortes, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.